Gary J Kelloff
Overview
Explore the profile of Gary J Kelloff including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
42
Citations
1916
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Sweeney S, Hamadeh H, Abrams N, Adam S, Brenner S, Connors D, et al.
Cancer Res
. 2023 Jan;
83(8):1183-1190.
PMID: 36625851
The analysis of big healthcare data has enormous potential as a tool for advancing oncology drug development and patient treatment, particularly in the context of precision medicine. However, there are...
2.
Sweeney S, Hamadeh H, Abrams N, Adam S, Brenner S, Connors D, et al.
Cancer Res
. 2023 Jan;
83(8):1175-1182.
PMID: 36625843
Big data in healthcare can enable unprecedented understanding of diseases and their treatment, particularly in oncology. These data may include electronic health records, medical imaging, genomic sequencing, payor records, and...
3.
Anderson K, Auclair D, Adam S, Agarwal A, Anderson M, Avet-Loiseau H, et al.
Clin Cancer Res
. 2021 Jul;
27(19):5195-5212.
PMID: 34321279
The development of novel agents has transformed the treatment paradigm for multiple myeloma, with minimal residual disease (MRD) negativity now achievable across the entire disease spectrum. Bone marrow-based technologies to...
4.
Williams P, Forbes T, Lund S, Cole K, He H, Karlovich C, et al.
JCO Precis Oncol
. 2021 Jul;
5.
PMID: 34250423
Methods: In this phase I study, QCMs with 14 clinically relevant mutations representing single nucleotide variants, insertions or deletions (indels), translocations, and copy number variants were sourced from three commercial...
5.
Narayan P, Ghosh S, Philip R, Barrett J, McCormack R, Odegaard J, et al.
Oncologist
. 2020 Jun;
25(9):730-732.
PMID: 32510742
No abstract available.
6.
Keating S, Taylor D, Plant A, David Litwack E, Kuhn P, Greenspan E, et al.
Clin Transl Sci
. 2018 Mar;
11(3):267-276.
PMID: 29498218
The high-content interrogation of single cells with platforms optimized for the multiparameter characterization of cells in liquid and solid biopsy samples can enable characterization of heterogeneous populations of cells ex...
7.
Berry D, Zhou S, Higley H, Mukundan L, Fu S, Reaman G, et al.
JAMA Oncol
. 2017 May;
3(7):e170580.
PMID: 28494052
Importance: Minimal residual disease (MRD) refers to the presence of disease in cases deemed to be in complete remission by conventional pathologic analysis. Assessing the association of MRD status following...
8.
Anderson K, Auclair D, Kelloff G, Sigman C, Avet-Loiseau H, Farrell A, et al.
Clin Cancer Res
. 2017 Apr;
23(15):3980-3993.
PMID: 28428191
Treatment of myeloma has benefited from the introduction of more effective and better tolerated agents, improvements in supportive care, better understanding of disease biology, revision of diagnostic criteria, and new...
9.
Kelloff G, Sigman C, Scher H
Urol Oncol
. 2015 Mar;
33(6):295-301.
PMID: 25746942
Background: The Food and Drug Administration (FDA) has called for the use of analytically validated biomarkers that have strong evidence of being fit for purpose to identify patients likely to...
10.
Herbst R, Gandara D, Hirsch F, Redman M, LeBlanc M, Mack P, et al.
Clin Cancer Res
. 2015 Feb;
21(7):1514-24.
PMID: 25680375
The Lung Master Protocol (Lung-MAP, S1400) is a groundbreaking clinical trial designed to advance the efficient development of targeted therapies for squamous cell carcinoma (SCC) of the lung. There are...